Organization (Academic)
University of North Texas Health Science Center
ClinicalTrials.gov lists University of North Texas Health Science Center as lead sponsor of 31 trials. It has 1 active development program and 1 approved asset.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 1 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 1.4 trial starts a year over the five years to September, under the 5 a year the method needs. 1 trial is registered to start in 2027 or later.
Logo Unthscnews, via Wikimedia Commons, CC BY-SA 3.0. Shown to identify the organization; it may be a registered trademark.
This page covers University of North Texas Health Science Center: 31 lead-sponsored trials and 1 legal-entity registration. The parent company on record for University of North Texas Health Science Center is University of North Texas System, which does not have its own page on this site.
Disease areas (46)
Shown in this order: most trials first (counted at this company's own legal-entity record, not the consolidated group).
| Disease area | Trials |
|---|---|
| Pain | 8 |
| Back Pain | 7 |
| Low Back Pain | 5 |
| Substance-Related Disorders | 3 |
| Cognitive Dysfunction | 3 |
Showing 5 of 46 disease areas.
Trials by start year as sponsor or collaborator (18)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2023 | 5 |
| 2022 | 2 |
| 2021 | 2 |
| 2020 | 2 |
| 2019 | 3 |
| 2018 | 3 |
| 2017 | 2 |
| 2016 | 3 |
| 2014 | 2 |
Showing 10 of 18 years.
Recruitment duration, a model prediction: 2 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (1)
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| TUDCA | Hypertension | Phase 1/2 | 1 |
Approved assets (1)
| Drug | Trials |
|---|---|
| Duloxetine | 1 |
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 11% hit target (n=9) | 25% on time (n=8) |
CLIA clinical laboratory certificates (3)
Shown in this order: active first, then certificate type.
| Lab | Certificate | Status |
|---|---|---|
| UNT HEALTH | Certificate for PPM procedures | Terminated |
| UNT HEALTH SCIENCE CENTER | Certificate for PPM procedures | Terminated |
| UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER | Certificate of waiver | Terminated |
Biomarker capability evidence (23)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ATP12A | Trial sponsor | Named in trial inclusion criteria |
| ATP4A | Trial sponsor | Named in trial inclusion criteria |
| LBP | Trial collaborator | Primary endpoint in a Phase 3 trial |
| UST | Trial sponsor | Primary endpoint in a Phase 3 trial |
| ALB | Trial collaborator | Named in trial exclusion criteria |
Showing 5 of 23 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, and organization relationships.
Counted at group level under University of North Texas System: journals published in, us granted patents, latest dated events, and biomarkers this organization publishes on.